StockNews.com Downgrades Danaher (NYSE:DHR) to Hold

Danaher (NYSE:DHR) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts also recently issued reports on DHR. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price on the stock in a research report on Friday. Stifel Nicolaus increased their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a report on Wednesday, October 23rd. Raymond James reduced their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. UBS Group lowered their price target on shares of Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Finally, TD Cowen boosted their price objective on shares of Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research note on Wednesday, October 23rd. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $287.95.

Danaher Stock Up 0.2 %

DHR stock opened at $234.89 on Friday. The stock has a fifty day moving average of $246.92 and a 200-day moving average of $257.43. Danaher has a fifty-two week low of $222.53 and a fifty-two week high of $281.70. The company has a market capitalization of $169.66 billion, a price-to-earnings ratio of 44.83, a PEG ratio of 4.33 and a beta of 0.83. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the business earned $2.02 earnings per share. The company’s quarterly revenue was up 3.1% on a year-over-year basis. As a group, equities research analysts predict that Danaher will post 7.5 earnings per share for the current year.

Institutional Trading of Danaher

Several institutional investors have recently added to or reduced their stakes in the business. FMR LLC grew its holdings in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the last quarter. Legal & General Group Plc grew its holdings in Danaher by 2.4% in the 2nd quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after acquiring an additional 139,989 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after acquiring an additional 148,251 shares during the period. Fisher Asset Management LLC raised its stake in shares of Danaher by 2.6% during the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after acquiring an additional 116,299 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in shares of Danaher by 17.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after purchasing an additional 535,254 shares during the period. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.